News

Filter

Current filters:

None

37 to 46 of 97217 results

Strong top-line results for Poxel’s antidiabetic agent imeglimin

Strong top-line results for Poxel’s antidiabetic agent imeglimin

17-12-2014

France-based drug developer Poxel says that imeglimin, a novel compound in development to treat type…

DiabetesFranceHealthimegliminMerck SeronoPharmaceuticalPoxelResearch

KCR acquires project portfolio from Ukraine’s CRO AXIS

KCR acquires project portfolio from Ukraine’s CRO AXIS

17-12-2014

KCR, a Poland-based contract research organization (CRO), has recently acquired the whole portfolio of…

AXIS GroupKCRMergers & AcquisitionsPharmaceuticalResearchUkraine

Ipsen appoints François Garnier as executive vice president, general counsel

Ipsen appoints François Garnier as executive vice president, general counsel

17-12-2014

French drugmaker Ipsen has appointed François Garnier as executive vice president, general counsel of…

BoardroomFranceIpsenIpsen GroupPharmaceutical

New guidance provides optimism for securing life sciences patents in USA

New guidance provides optimism for securing life sciences patents in USA

17-12-2014

The US Patent and Trademark Office (USPTO) has released its 2014 Interim Guidance on Patent Subject Matter…

PatentsPharmaceuticalPrometheus LabsUS Patent and Trademark OfficeUSA

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

UCB, Advent and Avista Capital terminate $1.5 billion divestment agreement

UCB, Advent and Avista Capital terminate $1.5 billion divestment agreement

17-12-2014

Belgian drugmaker UCB and private equity firms Avista Capital and Advent International have mutually…

BelgiumBusiness FinanceConcertaGenericsUCB

Janssen returns rights of IBD drug GLPG1205 to Galapagos

Janssen returns rights of IBD drug GLPG1205 to Galapagos

17-12-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has returned the rights to…

GalapagosGastro-intestinalsJanssenJanssen PharmaceuticaLicensingPharmaceutical

37 to 46 of 97217 results

Back to top